The aim is to discover and enhance new TEAD inhibitors for treating hepatocellular carcinoma (HCC) effectively.
Novel TEAD inhibitors were screened for efficacy and optimized for better performance.
In vivo investigations assessed tumor growth inhibition rates.
The study focused on the potential of these inhibitors as therapeutic agents against HCC.
The lead TEAD inhibitor showed an IC50 of 248 ± 27.9 nM in vitro.
In vivo testing revealed a tumor growth inhibition (TGI) rate of 75%.
Overall findings suggest these inhibitors may significantly contribute to HCC treatment strategies.
Abstract
= 248 ± 27.9 nM) and in vivo (TGI = 75%). Overall, this study provides a novel scaffold for TEAD inhibitors, enabling more effective interventions against HCC.